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Abstract
Background: Historically, local control of recurrent sarcomas has been limited to radiotherapy when surgical re-resection
is not feasible. For metastatic carcinomas to the bone or soft tissue, radiotherapy and some interventional
radiology treatment along with other systemic therapies have been widely advocated due to the possibility of
disseminated disease. These techniques are effective in alleviating pain and achieving local control for some
tumor types, but it has not been effective for prolonged local control of most tumors. Recently, cryoablation has
been reported to have satisfactory results in lung and liver carcinoma treatment. In this study, we analyzed the
clinical outcome of CT-guided cryoablation for malignant bone and soft tissue tumors to elucidate potential
problems associated with this procedure.
Methods: Since 2011, 11 CT-guided cryoablations in 9 patients were performed for locally recurrent or metastatic
bone and soft tissue tumors (7 males and 2 females) at our institute. The patients’ average age was 74.8 years
(range 61–86) and the median follow up period was 24.1 months (range 5–48). Histological diagnosis included
renal cell carcinoma (n = 4), dedifferentiated liposarcoma (n = 2), myxofibrosarcoma (n = 2), chordoma (n = 1),
hepatocellular carcinoma (n = 1), and thyroid carcinoma (n= 1). Cryoablation methods, clinical outcomes, complications,
and oncological outcomes were analyzed.
Results: There were 5 recurrent tumors and 6 metastatic tumors, and all cases had contraindication to either surgery,
chemotherapy or radiotherapy. Two and 3 cycles of cryoablation were performed for bone and soft tissue
tumors, respectively. The average length of the procedure was 101.1 min (range 63–187), and the average
number of probes was 2.4 (range 2–3). Complications included 1 case of urinary retention in a patient with sacral
chordoma who underwent prior carbon ion radiotherapy, 1 transient femoral nerve palsy, and 1 minor wound
complication. At the final follow up, 4 patients showed no evidence of disease, 2 were alive with disease, and 3
died of disease.
Conclusions: Reports regarding CT-guided cryoablation for musculoskeletal tumors are rare and the clinical
outcomes have not been extensively studied. In our case series, CT-guided cryoablation had analgesic efficacy
and there were no cases of local recurrence post procedure during the follow-up period. Although collection of
further data regarding use of this technique is necessary, our data suggest that cryoablation is a promising
option in medically inoperable musculoskeletal tumors.
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Background
Recurrent and metastatic bone and soft tissue tumors
pose significant problems because of their refractory na-
ture. Re-resection of local sarcoma recurrence has the
potential to cure the patient, but it is often difficult to
treat because it is almost impossible to discern the ex-
tent of tumor infiltration after multiple operations [1].
Metastasis of carcinoma to the bone and soft tissue is
also challenging due to the morbidity of patients. Vari-
ous radiotherapy techniques have been reported to be
effective in alleviating pain and achieving local control.
Approximately 60 % of patients reportedly experience
pain relief after radiotherapy [2]. Recently, carbon ion
radiotherapy has been reported to be effective for local
control of certain unresectable sarcomas, but its long-term
outcomes require further analysis [3]. When radiation ther-
apy is contraindicated for specific reasons, locally recurrent
or metastatic bone and soft tissue tumor are often treated
by palliative care.
Cryoablation is a therapeutic procedure wherein hol-
low cryoprobes are inserted into the tumor, causing a
decrease in the local temperature below 40° C. Freezing
for longer than 1 min causes cell death and subsequent
thawing further ensures disruption of the cellular integrity
[4, 5]. Its effectiveness for alleviating pain has been re-
ported in musculoskeletal metastases from carcinomas,
but its utility in the curative intent for metastases and
local recurrence is scarce. Furthermore, only 2 case series
have reported the effectiveness of cryoablation for primary
musculoskeletal tumors [6, 7].
The purpose of this study was to assess the feasibility,
safety and efficacy of cryosurgical ablation for locally re-
current sarcoma and metastatic carcinomas.
Methods
The inclusion criteria included limited symptomatic
metastasis, soft tissue recurrence or recurrent skeletal
disease with either osteolytic or mixed osteolytic -
osteoblastic features. All the cases were contraindicated
for other treatments, such as surgery or radiotherapy,
due to comorbidity or prior irradiation. Specifically, the
reason behind cryoablation for sarcoma cases were as
follows: chordoma patient had underwent previous car-
bon ion radiation therapy, dedifferentiated liposarcoma
of the retroperitoneal was an 86-year-old male who was
determined to be inoperable due to his comorbidity,
and myxofibrosarcoma patient had undergone 4 previ-
ous surgeries and refused further aggressive treatment
such as an amputation. Osteoblastic lesions were ex-
cluded because local anesthesia was deemed insufficient
to establish a tract for placing the ablation device. All
lesions that were adjacent to vital structures such as
the nerves and bowels were excluded, unless they could
be displaced by injection of air to ensure safety (Fig. 1).
Laboratory examination was performed to rule out any
coagulation disease or infection. In total, 9 patients
underwent argon - helium cryoablation for difficult tu-
mors since 2011. The treatment was performed according
to the approval of Institutional Board of Keio University
School of Medicine (#20110088) because this treatment
has not been validated for these tumors in Japan. Written
informed consent was obtained from each participant in
accordance with the Declaration of Helsinki. Cryoablation
was performed on patients under local anesthesia, with an
argon - helium gas based CRYO Care System (Endocare,
Irvine, CA), and cryoprobes were utilized in a multiple
freeze - thaw cycle that was monitored with CT guidance
(Fig. 2). Multiple probes were placed to encompass the en-
tire lesion and 2 or 3 freeze - thaw cycles (20 min freeze
followed by 10 min thaw) were then performed. Each cycle
reached a temperature of -196 °C at the probe tip. During
cryoablation, the ice ball was periodically monitored using
CT to secure at least a 1-cm margin around the tumor.
The freezing duration was slightly adjusted to allow for
complete tumor coverage and avoidance of adjacent crit-
ical structures (Fig. 3). One freeze - thaw cycle was added
for soft tissue tumors to ensure complete tumor death in
the context of the lower thermal conductivity of fat tissue
that usually surrounds the tumor [8]. Upon removal of the
probes, the tracts were evaluated for possible bleeding,
Fig. 1 Locally recurrent, 3 cm, dedifferentiated liposarcoma in the retroperitoneal paravertebral region 1 year after initial surgery (a, b). c Under
CT guidance, air was transperitoneally infused to displace the bowel just adjacent to the recurrent tumor
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and anticoagulant was used whenever there was bleeding
from the cylinders. The average tumor size was 39.6 mm
(range 22–52 mm), and tumors were localized in the ilium
(n = 5), retroperitoneum (n = 2), thigh (n = 2), rib (n = 1),
and sacrum (n = 1). Serial MRI was analyzed post cryoa-
blation after 1, 3, 6, and 12 months. Lesions were defined
as locally controlled if there was no focal enlargement
according to the Response Evaluation Criteria in Solid
Tumors (version 1.1) [9] and if there was no enhancement
of the lesion upon gadolinium administration on MRI.
The Kaplan - Meier method was used to determine the
survival rate (GraphPad PRISM®4 software, GraphPad
Software, San Diego, CA).
Results
During the study period, 11 lesions from 9 patients were
treated using CT-guided cryoablation. Five recurrent
cases were all due to sarcoma. Three cases (2 renal cell
carcinoma cases and one hepatocellular carcinoma
case) underwent pre - procedural transcatheter arterial
embolization for preventing bleeding during cryoablation.
Two and 3 cycles of cryoablation were performed for bone
and soft tissue tumors, respectively. Technically, in all pro-
cedures, the ice ball successfully encompassed the entire
tumor, visualized as a low density region under CT. The
average procedure length was 101.1 min (range 63–187)
and the average number of utilized probes was 2.4 (range
2–3). Inflammation, depicted as a high intensity area on
MRI from the procedure, persisted for several months.
However, at the final follow - up, only the low-intensity re-
gion that was not enhanced after gadolinium application
persisted (Fig. 4). The complications included 1 case of
urinary retention in a patient with sacral chordoma who
underwent prior carbon ion radiotherapy, 1 transient
femoral nerve palsy, and 1 minor wound complication.
No post - cryoablation hemorrhage was observed, even
for highly vascular lesions, which was possibly due to
transcatheter arterial embolization performed prior to
the procedure. All patients were discharged 1 day after
the procedure. Local control was obtained in all cases;
however, 2 patients (1 dedifferentiated liposarcoma and
1 myxofibrosarcoma) developed local recurrence apart
Fig. 2 a, b Markers were placed on the left buttock to discern the optimal direction of probe insertion and cryoablation was performed under CT
guidance. c Two probes were inserted into the lesion, and an ice ball was monitored to secure at least a 1-cm margin around the tumor
Fig. 3 a, b. Multiple synergistic probes were inserted into the tumor to ensure complete encapsulation of the lesion by the ice ball. The ice ball
was periodically monitored using CT to secure at least a 1-cm margin around the tumor
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from the initial procedure. Both the patients subsequently
underwent a second cryoablation. At the final follow - up,
4 patients showed no evidence of disease and 2 were alive
with disease, but 3 patients died due to systemic tumor
metastasis. The median survival for the entire group was
35 months (Fig. 5).
Discussion
Local control is typically achieved in approximately
60–90 % of sarcomas after wide resection, depending
on the tumor location [10, 11]. Various methods, from
local adjuvant therapies to novel molecular therapeutics,
have the potential to further improve the outcome; how-
ever, the prognosis has not improved in the past decades
possibly due to the difficulty when facing local recurrence
and distant metastasis [12]. Although re-resection with or
without radiotherapy is the gold standard for local re-
currence of sarcomas, further surgery is often not
feasible because of the uncertain spread of the lesion
under imaging, the lack of an adequate barrier in add-
itional wide resection and patient morbidity after multiple
operations and systemic therapies [13, 14] . Furthermore,
bone metastasis of sarcomas is a debilitating event that
impairs the quality of life. Local recurrences have been
reported to worsen the outcome due to consequent me-
tastasis [15]. Metastasis of carcinomas is also difficult to
treat, owing to patient morbidity after extensive treatment
of the primary lesion. Carcinomas usually present with
systematic metastasis which limits the treatment to radio-
therapy or various interventional radiology treatment. The
outcome of bone metastasis has seen great improvement
through the advent of bone modifying agents such as
bisphosphonates and anti - RANKL antibody, denosumab.
However, there are also side effects, such as osteonecrosis
of the jaw and atypical fractures. Metastasis to soft tissue
is problematic when it causes a mass effect or compres-
sion of vital organs. Some cancers have improved after ex-
cision of the tumor bulk, such as in oligometastatic cases,
but surgery is often challenging when it occurs in deep-
seated locations. Reducing the sarcoma burden has been
implicated as an adjunct to aggressive salvage chemother-
apy [16, 17]. With the advent of newer drugs targeting
molecular susceptibility, novel minimally invasive tech-
niques, such as cryoablation, could be integrated for future
treatment.
There has been wide variety of image guided thermal
ablations, including radiofrequency, microwave, laser,
high intensity ultrasound, irreversible electroporation,
and cryotherapy. Percutaneous thermal ablation offers
minimal invasive procedures, but each technique has
their own clinical applications. Radiofrequency was the
first reported percutaneous thermal ablation technique,
and its efficacy has been widely reported for various
tumor types. It is especially effective for small lesions,
such as osteoid osteoma, for which the heat is sufficient
to eradicate lesions that are usually less than 2 cm in
diameter [18]. However, a limitation is that the area of
ablation is not readily visualized under imaging mo-
dalities [19]. Other techniques that utilize laser and
ultrasound technology have also shown efficacy, albeit
Fig. 4 Gadolinium enhanced T1 - weighted MR image with fat suppression of an iliac metastasis from thyroid carcinoma (a) and 6 months after
cryoablation (b). The effect of cryoablation is depicted as a low-signal intensity area with rim enhancement. The low-intensity area persisted during
the 3 - year follow - up, a result consistent with no local recurrence
Fig. 5 Kaplan - Meier survival curve analysis of the entire group.
There was no local recurrence after cryoablation and the median
survival was 35 months
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in small case series for musculoskeletal tumors. Laser
ablation is primarily employed in small lesions, such as
osteoid osteoma, and high - intensity focused ultrasound is
limited to surface lesions because an appropriate acoustic
window under MRI is necessary for this technology [20].
Cryotherapy was first reported in the mid - 19th century
[21], and its percutaneous application was subsequently
modified for musculoskeletal tumors [22]. Cryotherapy
has a strong advantage in that it can treat irregularly
shaped lesions by using multiple synergistic probes as well
as monitor the area of ablation, as an ice ball, to ensure ac-
curacy. Furthermore, unlike with radiotherapy, it can be
applied repeatedly. Additionally, the post procedural pain
is minimal, and recovery is swift with the possible additive
effect of a systemic antitumor immune response by cryoa-
blation [23].
The effectiveness of cryoablation for palliating pain
from cancer metastasis has been reported by several
groups [20, 24]. Furthermore, cryoablation has been able
to achieve local control of asymptomatic cancer metasta-
sis with limited systematic spread. In a single center
retrospective study, local control was achieved for over
85 % of metastases at a median time of 21 months [25].
Additionally, cryoablation for oligometastatic renal cell
carcinoma has been implicated to result in higher overall
survival compared to systematic treatments alone [26].
Recently, there have been sporadic reports of the use of
cryoablation for soft tissue sarcomas [22, 27]. In a recent
feasibility study with soft tissue sarcoma relapse, location
in the wall of the trunk, shoulders and pelvic girdle; tu-
mors with local aggressiveness; deep tumors or tumors
less or equal to 5 cm, and liposarcoma and myxofibrosar-
coma were deemed suitable for cryoablation [27]. Although
the study populations are generally small, improved local
control, analgesic efficacy, reduced complication and
reduction of convalescence after the procedure has been
reported [28].
Clinically, the disadvantages of cryoablation include its
medical cost (it is not covered by the National Health
Insurance in Japan), the necessity of an argon gas supply,
equipment maintenance, and a large storage area [29].
Technically, there are several limitations to this proced-
ure: the lesion should have an adequate distance from
the skin, neurovascular structure and other viscera, and
should not be localized in a weight - bearing bone. The
average time of the procedure has been longer than for
other percutaneous thermal ablation techniques performed
at our institute (data not shown).
There are a few limitations in the present study. Most
critically, the sample size is relatively small, as is the case
for past reports using a small case series. The wide dif-
ferences in follow - up duration stems from the lack of
insurance coverage for this procedure in Japan which
costs approximately 9000 U.S. dollars. This has been the
major obstacle in recruiting large number of patients. In
addition, the results may have been biased because only
relatively small sized lesions were included in the study.
Nevertheless, ablation for asymptomatic metastases or
local recurrence for local control has not been thor-
oughly reported, and our data should provide a basis for
further clinical studies to clarify the efficacy of this tech-
nique in treating such patients.
Conclusion
The outcomes from this study suggest that cryoablation
is clinically safe and feasible, because no local recurrence
was observed in any of the cases. Further prospective ran-
domized studies are warranted to elucidate the optimum
protocol for this technique and effectiveness for a variety
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